Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

NAD+ vs SS-31: Which Better Comparison

Primary Mechanism Restores NAD+ pools to activate sirtuins, PARPs, and support mitochondrial biogenesis via PGC-1α Stabilizes cardiolipin in the inner mitochondrial membrane, preventing oxidative damage to electron transport chain complexes NAD+ is substrate r

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Primary Mechanism
  • Restores NAD+ pools to activate sirtuins, PARPs, and support mitochondrial biogenesis via PGC-1α
  • Stabilizes cardiolipin in the inner mitochondrial membrane, preventing oxidative damage to electron transport chain complexes
  • NAD+ is substrate restoration; SS-31 is structural protection. Choose based on whether the pathology is energy depletion or membrane damage.
  • Evidence Strength
  • Consistent elevation of blood/tissue NAD+ levels; inconsistent clinical endpoints across metabolic and cognitive trials
  • Strong preclinical efficacy in ischemia and aging models; clinical benefit confirmed in Barth syndrome; mixed results in heart failure
  • NAD+ has broader trial data but weaker outcomes. SS-31 has fewer trials but more consistent functional benefits in targeted populations.
  • Onset of Measurable Effect
  • NAD+ levels rise within 2–4 weeks; functional benefits (if present) appear at 8–12 weeks
  • Cardiolipin stabilization is immediate; functional outcomes (walk distance, cardiac function) measurable at 8–12 weeks
  • Both compounds require sustained use for clinical outcomes. Acute dosing doesn't produce lasting effects.
  • Typical Research Dose Range
  • NMN: 250–1,000 mg/day oral; NR: 500–1,000 mg/day oral
  • 40 mg/day subcutaneous or IV (clinical trials); 1–5 mg/kg in preclinical models
  • SS-31 is administered parenterally in trials. Oral bioavailability is negligible due to peptide degradation in the GI tract.
  • Target Pathologies
  • Metabolic dysfunction, insulin resistance, age-related NAD+ depletion, mild cognitive impairment
  • Mitochondrial myopathies, heart failure, ischemia-reperfusion injury, neurodegenerative diseases with oxidative stress
  • NAD+ suits early-stage dysfunction; SS-31 suits advanced pathology with confirmed membrane damage.
  • Limitations
  • Does not prevent oxidative membrane damage; effects disappear within weeks of stopping; high oral doses required
  • Does not restore NAD+ pools; requires injection; limited trial data in healthy aging populations
  • Neither compound addresses all aspects of mitochondrial decline. Combination protocols are increasingly standard in aging research.

Related resources

More comparisons